Navigation Links
Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
Date:3/31/2009

>

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America, Europe, Japan and Taiwan. Clevudine is already approved for HBV in South Korea and the Philippines. It is marketed in Korea by Bukwang Pharmaceuticals under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche, and is initiating a Phase 2b trial. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involvin
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Reports Fiscal Year End 2008 Financial Results
2. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
3. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
4. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
5. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
6. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
8. Pharmasset Receives Notice of Allowance
9. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
10. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
11. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Pharmaceutical Care Management Association (PCMA) President and CEO ... reduce prescription fraud and abuse in Medicare Part D ... Fighting Back on Many Fronts ," sponsored by the ... The briefing featured several government and industry experts discussing ... Centers for Disease Control and Prevention has labeled the ...
(Date:9/29/2014)... CITY , Sept. 29, 2014 ... scheduled a conference call for investors today at ... the quarter and year ended June 30, 2014.  ... participating is (800) 771-7941. Dynatronics manufactures, ... goods and supplies, treatment tables and rehabilitation equipment ...
(Date:9/29/2014)... 2014 EU5 Esophagoscopes & Gastroscopes Market ... report, "EU5 Esophagoscopes & Gastroscopes Market Outlook to ... Esophagoscopes & Gastroscopes market. The report provides value, ... and average prices (in US dollars) within market ... Gastroscopes and Flexible Video Gastroscopes. ...
Breaking Medicine Technology:PCMA: How Congress Can Fight Prescription Drug Fraud and Abuse 2EU5 Esophagoscopes & Gastroscopes Market Outlook to 2020 2EU5 Esophagoscopes & Gastroscopes Market Outlook to 2020 3
... Target Enrollment Expected in Fourth Quarter, BERKELEY ... GNTA ) announced that the Data Safety Monitoring ... Genasense (oblimersen sodium),Injection, which is the Company,s lead ... as originally planned after initial review of,blinded safety ...
... unique Ranexa(R) mechanism of action -, CHICAGO, March ... today that ranolazine significantly (p<0.001),shortened the QT interval of ... LQT3, which is caused by a genetic mutation in ... rhythm problems, including,sudden death. Ranolazine also shortened cardiac relaxation ...
Cached Medicine Technology:DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 2DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 3DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 4Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 2Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 3
(Date:9/30/2014)... Pyramid Analytics, worldwide leader in Governed ... of Veterans Affairs has selected Pyramid Analytics ... Business Intelligence platform. This partnership will enable the ... enabling more than 30,000 users with insights that ... and reporting capabilities. , The strategic selection comes ...
(Date:9/30/2014)... “Biology and botany are having ... “and it’s about naming rights.” , In ... on the Bryan William Brickner Blog, the focus ... of Health (PubMed). The post highlights five cannabinoid ... transitions, aging with THC, the wake-inducing effects of ...
(Date:9/30/2014)... September 30, 2014 A trailblazer at heart, ... seeks out upcoming medical breakthroughs in spine repairs. His ... seen in his patients in which he has implanted the ... its components are state-of-the art and mimic normal human disc ... has also been proven to be an exceptional replacement device ...
(Date:9/30/2014)... 30, 2014 3M has added four new ... bond tapes. 3M 5906 , 3M 5907 , ... conformable VHBs which help create the strongest bond possible to ... used for bonding to difficult surfaces such as paints, low ... 5907, 5908, and 5905 are designed specifically for electronic device ...
(Date:9/30/2014)... Dogs are social animals, and love to go everywhere with ... travelling from place to place. Many dog owners choose to ... this is not only unsafe for the dog, but unsafe ... shares with readers why keeping a dog restrained in a ... ways a dog can become injured by riding freely in ...
Breaking Medicine News(10 mins):Health News:U.S. Department of Veterans Affairs Takes Its Analytic Capabilities to the Next Level with BI Office from Pyramid Analytics 2Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 2Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 3
... June 7th, Little Hearts, Inc. held their 13th annual celebration ... services they offer is their "Picture of Hope" -- a ... from infant to 50 of all different types of heart ... and Tricuspid Atresia. "HOPE" is shared with others on ...
... two hours of slumber a night, study suggests , MONDAY, ... computer games can be a nocturnal nightmare for some people, ... sleep at night, then spend their days struggling to stay ... between the two, the study found. , The study revealed ...
... 8 Taste and nutrition have long been topics ... so much uncertainty about what products are healthy in ... way by delivering delicious, convenient and nutritious foods to ... the release of Sunsweet Antioxidant Blend, a delicious combination ...
... the Shelves for Father,s Day , , NEW YORK, June ... back pain may lie in a $59.99 biomechanically-engineered foam and rubber ... point for the sixty million adults who reported persistent back pain ... to be a medical breakthrough is now available in the Dass, ...
... -- Eating disorders are a chronic mental health ... 1 million males in the United States. Through access ... organizations (IROs) provide a simple and lasting solution to ... and laxative abuse. Additionally they deliver the appropriate standard ...
... Cedars-Sinai Outpatient Cancer Center Appointed COO , , ... today announced the appointment of Paul R. O,Dea to ... formerly Vice President, Aptium Oncology and Executive Director, Cedars-Sinai ... hospital-based cancer centers. The appointment was effective June 1, ...
Cached Medicine News:Health News:Members of National CHD Organization Unite for Little Hearts' Celebration and Assemble for 'Picture of Hope' 2Health News:Too Much Computer Gaming Can Steal Your Sleep 2Health News:Too Much Computer Gaming Can Steal Your Sleep 3Health News:Sunsweet Introduces New Antioxidant Blend, a Delicious Blend of High Antioxidant Fruits 2Health News:Sunsweet Introduces New Antioxidant Blend, a Delicious Blend of High Antioxidant Fruits 3Health News:One of Women's Best Kept Secrets is Now Available in the Men's Department 2Health News:Health Plans and IROs Can Work Together to Determine Proper Care for Eating Disorders 2Health News:Aptium Oncology Names New Chief Operating Officer 2
... Elite II features a diagnostic ... of Glasgow,(UG) algorithm. Unlike competitive ... age, the UG,algorithm bases its ... gender, age, race, medication,and classification., ...
... test face is a LogMAR ... Landolt C in various orientations ... targets are presented at 10% ... useful for evaluating the low ...
The CSV-1000-1.5CPD is a special test face designed specifically for Food and Drug Administration clinical trials., ,At the recommended test distance of 8 feet, the gratings test one spatial frequenc...
... test face is used widely for screening ... LogMAR acuity from 20/10 to 20/100 and ... cycles/degree. , ,The patient can be easily ... acuity and contrast sensitivity. If a contrast ...
Medicine Products: